Kaiser, Jon D · International journal of clinical and experimental medicine · 2015
This small study tested a combination treatment called KPAX002, which pairs a stimulant medication (methylphenidate) with nutrients thought to support energy production in cells. Fifteen people with ME/CFS took this combination for 12 weeks, and researchers measured changes in fatigue and concentration problems using standard questionnaires. Most participants (87%) showed meaningful improvement in fatigue, and the treatment was generally safe and well tolerated.
ME/CFS lacks effective pharmacological treatments, and this is among the first studies to systematically investigate a combination approach. The high response rate (87%) and statistical significance warrant further investigation to determine if synergy between stimulant and mitochondrial support strategies could benefit patients. Rigorous follow-up trials are needed to establish whether these encouraging preliminary results reflect true efficacy or placebo effects.
This study does not prove KPAX002 is effective for ME/CFS because there was no control or placebo group—symptom improvements could reflect natural variation, placebo effect, or regression to the mean. The small sample size (15 patients) limits generalizability. The study also cannot identify which component (methylphenidate, micronutrients, or their combination) drove any observed benefits.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →